

Dated: March 9, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-05256 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH23-003, Conducting Public Health Research With Universities in Thailand; Amended Notice of Closed Meeting

Notice is hereby given of a change in the meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH23-003, Conducting Public Health Research with Universities in Thailand; April 12, 2023, 9 a.m.–2:30 p.m., EDT, teleconference, in the original **Federal Register** Notice. The meeting was published in the **Federal Register** on March 2, 2023, Volume 88, Number 41, page 13121.

The meeting is being amended to add a Notice of Funding Opportunity number and should read as follows:

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—GH20-002, Malaria Operations Research to Improve Malaria Control and Reduce Morbidity and Mortality in Western Kenya; and GH23-003, Conducting Public Health Research with Universities in Thailand.

The meeting is closed to the public.

FOR FURTHER INFORMATION CONTACT: Hylan Shoob, Ph.D., Scientific Review Officer, Center for Global Health, CDC, 1600 Clifton Road NE, Mailstop H21-9, Atlanta, Georgia 30329-4027; Telephone: (404) 639-4796; Email: HShoob@cdc.gov.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and

Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-05297 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with regulatory provisions, the Centers for Disease Control and Prevention (CDC) announces the following meeting for the Clinical Laboratory Improvement Advisory Committee (CLIAC). This meeting is open to the public, limited only by the number of webcast lines available. Time will be available for public comment.

DATES: The meeting will be held on April 12, 2023, from 11 a.m. to 5:30 p.m., EDT, and April 13, 2023, from 11 a.m. to 5 p.m., EDT.

ADDRESSES: This is a virtual meeting. Meeting times are tentative and subject to change. The confirmed meeting times, agenda items, and meeting materials, including instructions for accessing the live meeting broadcast, will be available on the CLIAC website at <https://www.cdc.gov/cliac>. Check the website on the day of the meeting for the web conference link.

FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, Senior Advisor for Clinical Laboratories, Division of Laboratory Systems, Office of Laboratory Science and Safety, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop V24-3, Atlanta, Georgia 30329-4027. Telephone: (404) 498-2769; Email: HStang@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The Clinical Laboratory Improvement Advisory Committee (CLIAC) is charged with providing scientific and technical advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; the Director, CDC; the Commissioner, Food and Drug Administration (FDA); and the Administrator, Centers for Medicare &

Medicaid Services (CMS). The advice and guidance pertain to general issues related to improvement in clinical laboratory quality and laboratory medicine and specific questions related to possible revision of the Clinical Laboratory Improvement Amendments of 1988 (CLIA) standards. Examples include providing guidance on studies designed to improve quality, safety, effectiveness, efficiency, timeliness, equity, and patient-centeredness of laboratory services; revisions to the standards under which clinical laboratories are regulated; the impact of proposed revisions to the standards on medical and laboratory practice; and the modification of the standards and provision of non-regulatory guidelines to accommodate technological advances, such as new test methods, the electronic transmission of laboratory information, and mechanisms to improve the integration of public health and clinical laboratory practices.

Matters To Be Considered: The agenda will include agency updates from CDC, CMS, and FDA. Presentations and CLIAC discussions will focus on reports from two CLIAC workgroups: the CLIA Regulations Assessment Workgroup and the CLIA Certificate of Waiver and Certificate for Provider-performed Microscopy Procedures Workgroup, and on the laboratory's role in advancing health equity. Agenda items are subject to change as priorities dictate.

Public Participation

It is the policy of CLIAC to accept written public comments and provide a brief period for oral public comments pertinent to agenda items.

Oral Public Comment: Public comment periods for each agenda item are scheduled immediately prior to the Committee discussion period for that item. In general, each individual or group requesting to present an oral comment will be limited to a total time of five minutes (unless otherwise indicated). Speakers should email CLIAC@cdc.gov or notify the contact person above (see **FOR FURTHER INFORMATION CONTACT**) at least five business days prior to the meeting date.

Written Public Comment: CLIAC accepts written comments until the date of the meeting (unless otherwise stated). However, it is requested that comments be submitted at least five business days prior to the meeting date so that the comments may be made available to the Committee for their consideration and public distribution. Written comments should be submitted by email to CLIAC@cdc.gov or to the contact person above. All written comments will be

included in the meeting minutes posted on the CLIAC website.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-05294 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single-Source Cooperative Agreement To Fund the Haitian Ministry of Health and Population

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), in the Department of Health and Human Services (HHS), announces the award of approximately \$15,000,000, for Year 1 funding to the Haitian Ministry of Health and Population (MSPP). The award will strengthen the public health system in Haiti by building the capacity of MSPP and partners to sustain governance of public health programs and, laboratory quality systems, monitor and evaluate programs, conduct surveillance for priority diseases and conditions (including, but not limited to, HIV, TB, cholera, VPDs, malaria, AFP, LF, rabies, COVID), and provide high quality health services. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2023, through September 29, 2028.

FOR FURTHER INFORMATION CONTACT: Chen Chung, Center for Global Health, Centers for Disease Control and Prevention, Boulevard 15 Octobre, Tabarre 41 Port-au-Prince, Haiti, Telephone: (509) 3170-3493, Email: htt0@cdc.gov.

SUPPLEMENTARY INFORMATION: The single-source award will strengthen

public health systems in Haiti to maximize the positive impact of the MSPP on the HIV and TB response, disease surveillance, emergency preparedness, workforce development, immunization, and other programs to achieve and sustain epidemic control as well as prevent or mitigate future outbreaks.

The MSPP is in a unique position to conduct this work, as it has the statutory authority to develop and oversee the information and surveillance system related to all diseases and is the only line ministry having the presence in the 10 geographical departments of the country and as such maintains 10 directorates equipped with both technical and administrative capacity.

Summary of the Award

Recipient: The Haitian Ministry of Health and Population (MSPP).

Purpose of the Award: The purpose of this award is to strengthen the public health system in Haiti by building the capacity of MSPP and partners to sustain governance of public health programs and, laboratory quality systems, monitor and evaluate programs, conduct surveillance for priority diseases and conditions (including, but not limited to, HIV, TB, cholera, VPDs, malaria, AFP, LF, rabies, COVID), and provide high quality health services.

Amount of Award: The approximate year 1 funding amount will be \$15,000,000 in Federal Fiscal Year (FFY) 2023 funds, subject to the availability of funds. Funding amounts for years 2–5 will be set at continuation.

Authority: This program is authorized under Public Law 108–25 (the United States Leadership Against HIV AIDS, Tuberculosis and Malaria Act of 2003).

Non-PEPFAR Funding

Additionally, this program is authorized under sections 301(a) and 307 of the Public Health Service Act, as amended [42 U.S.C. 241(a) and 2421].

Period of Performance: September 30, 2023 through September 29, 2028.

Dated: March 9, 2023.

Terrance Perry,

Chief Grants Management Officer, Centers for Disease Control and Prevention.

[FR Doc. 2023-05248 Filed 3-14-23; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Notice of Award of a Single-Source Cooperative Agreement To Fund the National Institute of Health (INS) in Mozambique

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice.

SUMMARY: The Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), announces the award of approximately \$4,000,000, for Year 1 funding to the INS. The award will strengthen and support the INS in Mozambique to improve INS's operational capacity in laboratory systems and testing, disease surveillance, M&E, and human resources. Funding amounts for years 2–5 will be set at continuation.

DATES: The period for this award will be September 30, 2023, through September 29, 2028.

FOR FURTHER INFORMATION CONTACT:

Rachel Murray, Center for Global Health, Centers for Disease Control and Prevention, Avenida Marginal nr 5467 Sommerschild, Distrito Municipal de KaMpfumo Caixa Postal 783 CEP 0101-11 Maputo, Moçambique, Telephone: +258 84 310 8384, Email: kve0@cdc.gov.

SUPPLEMENTARY INFORMATION: The single-source award will strengthen the capacity of the national laboratory network to provide quality diagnostic testing and public health laboratory services.

The INS is in a unique position to conduct this work, as it is mandated to manage, regulate, and supervise activities related to the generation of scientific evidence in the field of health to ensure better health and well-being for the population of Mozambique.

Summary of the Award

Recipient: National Institute of Health (INS) in Mozambique.

Purpose of the Award: The purpose of this award is to strengthen and support the INS in Mozambique to improve INS's operational capacity in laboratory systems and testing, disease surveillance, M&E, and human resources.

Amount of Award: The approximate year 1 funding amount will be \$4,000,000 in Federal Fiscal Year (FFY) 2023 funds, subject to the availability of